Initial Treatment of Aumolertinib in Combination with Bevacizumab for Advanced NSCLC with Primary EGFR T790M Mutation: A Report of Three Cases and Literature Review

Initial Treatment of Aumolertinib in Combination with Bevacizumab for Advanced NSCLC with Primary EGFR T790M Mutation: A Report of Three Cases and Literature Review

With the development of sequencing technology, the detection rate of non-small cell lung cancer (NSCLC) with primary epidermal growth factor receptor (EGFR) T790M mutation is increasing. However, the first-line treatment for primary EGFR T790M-mutated NSCLC still lacks standard recommendations. Here...

Full description

Bibliographic Details
Main Authors: Xue YANG, Fanlu MENG, Diansheng ZHONG
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2023-02-01
Series:Chinese Journal of Lung Cancer
Subjects:
aumolertinib
primary t790m
bevacizumab
lung neoplasms
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.04

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.04

Similar Items